Comparative Bacteriological Efficacy of Pharmacokinetically Enhanced Amoxicillin-Clavulanate against Streptococcus pneumoniae with Elevated Amoxicillin MICs and Haemophilus influenzae
Open Access
- 1 March 2005
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (3), 908-915
- https://doi.org/10.1128/aac.49.3.908-915.2005
Abstract
A new pharmacokinetically enhanced formulation of amoxicillin-clavulanate (2,000 mg of amoxicillin/125 mg of clavulanate twice a day; ratio 16:1) has been designed, with sustained-release technology, to allow coverage of bacterial strains with amoxicillin-clavulanic acid MICs of at least 4/2 μg/ml. The bacteriological efficacy of amoxicillin-clavulanate, 2,000/125 mg twice a day, ratio 16:1, was compared in a rat model of respiratory tract infection versus four other amoxicillin-clavulanate formulations: 8:1 three times a day (1,000/125 mg), 7:1 three times a day (875/125 mg), 7:1 twice a day (875/125 mg), and 4:1 three times a day (500/125 mg); levofloxacin (500 mg once a day); and azithromycin (1,000 mg on day 1 followed thereafter by 500 mg once a day). Bacterial strains included Streptococcus pneumoniae , with amoxicillin-clavulanic acid MICs of 2/1 (one strain), 4/2, or 8/4 μg/ml (three strains each), and Haemophilus influenzae , one β-lactamase-positive strain and one β-lactamase-negative, ampicillin-resistant strain. Animals were infected by intrabronchial instillation. Antibacterial treatment commenced 24 h postinfection, with doses delivered by computer-controlled intravenous infusion to approximate the concentrations achieved in human plasma following oral administration. Plasma concentrations in the rat corresponded closely with target human concentrations for all antimicrobials tested. Amoxicillin-clavulanate, 2,000/125 mg twice a day, ratio 16:1, was effective against all S. pneumoniae strains tested, including those with amoxicillin-clavulanic acid MICs of up to 8/4 μg/ml and against β-lactamase-producing and β-lactamase-negative ampicillin-resistant H. influenzae . These results demonstrate the bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate 2,000/125 mg twice a day (ratio 16:1) against S. pneumoniae with amoxicillin-clavulanic acid MICs of at least 4/2 μg/ml and support clavulanate 125 mg twice a day as sufficient to protect against β-lactamase in this rat model.Keywords
This publication has 24 references indexed in Scilit:
- How can we predict bacterial eradication?International Journal of Infectious Diseases, 2003
- Effects of an Efflux Mechanism and Ribosomal Mutations on Macrolide Susceptibility of Haemophilus influenzae Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2003
- Failure of Macrolide Antibiotic Treatment in Patients with Bacteremia Due to Erythromycin‐ResistantStreptococcus pneumoniaeClinical Infectious Diseases, 2002
- Resistance to Levofloxacin and Failure of Treatment of Pneumococcal PneumoniaNew England Journal of Medicine, 2002
- Levofloxacin Treatment Failure in a Patient with Fluoroquinolone‐Resistant Streptococcus pneumoniae PneumoniaPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2002
- Efficacies of ABT-773, a New Ketolide, against Experimental Bacterial InfectionsAntimicrobial Agents and Chemotherapy, 2001
- Levofloxacin Failure in a Patient with Pneumococcal PneumoniaAnnals of Pharmacotherapy, 2001
- The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanateClinical Therapeutics, 2001
- Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection.Journal of Antimicrobial Chemotherapy, 2000
- Efficacy of High-Dose Amoxicillin-Clavulanate against Experimental Respiratory Tract Infections Caused by Strains of Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 1999